— EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ (glecaprevir/pibrentasvir) in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)
— In cohort one, 100 percent of genotype 1, 2, 4, 5 and 6 treatment-naïve chronic HCV patients with compensated cirrhosis achieved SVR with 8 weeks of MAVYRET per protocol analysis
— Cohort two of the study is ongoing, evaluating treatment-naïve genotype 3 (GT3) patients with compensated cirrhosis
— MAVYRET is currently approved as an 8-week, pan-genotypic treatment for treatment-naïve patients without cirrhosis
Read the full press release here.